News
HALO
69.62
+0.91%
0.63
LifeMD partners with Halozyme subsidiary for exclusive testosterone program
TipRanks · 1d ago
LifeMD partners with Halozyme unit Antares to launch XYOSTED telehealth self-pay program in July 2026
PUBT · 1d ago
Weekly Report: what happened at HALO last week (0615-0619)?
Weekly Report · 1d ago
Did Expanding ENHANZE Partnerships and Cash Generation Just Shift Halozyme Therapeutics' (HALO) Investment Narrative?
Simply Wall St · 4d ago
As corporate profit margins remain elevated, these mid-caps stand out
Seeking Alpha · 5d ago
Halozyme Therapeutics (HALO) Stock Could Be 18.8% Undervalued As Partner Growth Lifts Sentiment
Simply Wall St · 6d ago
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), SAB Biotherapeutics (SABS) and Design Therapeutics (DSGN)
TipRanks · 06/15 11:50
Halozyme Buy Rating Reiterated as Analyst Sees Limited Medicare Pricing Risk and Maintains $93 Price Target
TipRanks · 06/15 11:45
Analysts Conflicted on These Healthcare Names: Incyte (INCY), Intellia Therapeutics (NTLA) and Halozyme (HALO)
TipRanks · 06/15 10:50
Halozyme Sees Little Royalty Impact From Medicare Drug Pricing Rule, Says CMS Proposal Should Not Hurt ENHANZE Partnerships
Benzinga · 06/15 10:14
Halozyme sees zero to minimal royalty hit through at least 2035 under draft Medicare drug pricing rule
PUBT · 06/15 10:00
HALOZYME CONFIRMS IT PROJECTS ZERO TO MINIMAL IMPACT TO ROYALTY REVENUE THROUGH AT LEAST 2035 BASED ON NEWLY RELEASED DRAFT MEDICARE DRUG PRICE NEGOTIATION PROGRAM PROPOSED RULE FOR IPAY 2029
Reuters · 06/15 10:00
Weekly Report: what happened at HALO last week (0608-0612)?
Weekly Report · 06/15 09:04
J&J multiple myeloma drug Talvey cuts mortality risk by up to 53% in late-stage trial
Seeking Alpha · 06/13 12:54
Halozyme Therapeutics (HALO) Up 0.8% Since Last Earnings Report: Can It Continue?
NASDAQ · 06/10 15:30
Halozyme names Darren Snellgrove SVP, CFO in initial beneficial ownership filing
PUBT · 06/09 20:59
Weekly Report: what happened at HALO last week (0601-0605)?
Weekly Report · 06/08 09:03
A Look At Halozyme Therapeutics (HALO) Valuation After New ENHANZE Data And Analyst Buy Reaffirmation
Simply Wall St · 06/05 11:36
What Halozyme Therapeutics (HALO)'s New ENHANZE Partner Data and Analyst Support Means For Shareholders
Simply Wall St · 06/04 06:29
Halozyme publishes 2025 greenhouse gas accounting summary report
PUBT · 06/03 19:54
More
Webull provides a variety of real-time HALO stock news. You can receive the latest news about Halozyme Thrp through multiple platforms. This information may help you make smarter investment decisions.
About HALO
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.